Getting Insurance Coverage for Wegovy & Zepbound in 2025: Your Comprehensive Guide to Coverage and Winning Appeals

Eric Eden

11 May 2025 • 54 min read

Introduction: A New Era for Weight Management (and How to Pay for It)

The Promise and the Puzzle

The arrival of medications like Wegovy and Zepbound has marked a significant advancement in the approach to weight management and its associated health conditions. For many individuals, these treatments represent a new sense of hope and a pathway to improved health. Wegovy, for instance, is recognized as the most widely prescribed and studied GLP-1 medication for weight loss.¹ Similarly, Zepbound is anticipated to be a leading medication in 2025, partly due to its increasing availability and newly approved uses.² This growing demand underscores the importance of understanding how to access these potentially life-changing drugs.

However, alongside the promise of these medications comes a common and often significant challenge: navigating the complexities of insurance coverage. For many patients, obtaining approval and affording these treatments can feel like trying to solve an intricate puzzle, leading to frustration and anxiety.

Empowering Your Journey

This guide is designed to serve as a comprehensive resource, equipping individuals with the knowledge and practical tools needed to confidently approach the insurance system. While the path to securing coverage for Wegovy or Zepbound can seem daunting, understanding the process is the crucial first step toward successfully accessing these therapies. The aim here is to provide clear, actionable information that empowers patients in their healthcare journey.

What This Guide Covers

This article will walk through the essential aspects of obtaining Wegovy and Zepbound in 2025. It begins with a foundational understanding of these medications – what they are, how they work, and their approved uses. It then delves into the current insurance landscape, explaining the general trends in coverage across different types of plans. Detailed sections will demystify the prior authorization process, offer step-by-step guidance on how to effectively appeal an insurance denial, and explore various financial assistance programs. Finally, for situations where coverage remains elusive, alternative treatment options will be discussed.

Understanding Wegovy and Zepbound in 2025: What You Need to Know

Before diving into the intricacies of insurance, it's important to have a solid understanding of Wegovy and Zepbound. This knowledge will be invaluable when discussing treatment options with healthcare providers and communicating with insurance companies.

What They Are and How They Work (Keeping it Simple)

Wegovy (semaglutide): Wegovy is a medication that belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. In simpler terms, it works by mimicking a natural hormone in the gut called GLP-1. This hormone plays a role in regulating appetite and food intake. Wegovy targets areas in the brain that control hunger, helping individuals feel fuller for longer periods and thereby reducing their overall calorie consumption.³ Additionally, it slows down the process of stomach emptying and can influence blood sugar levels by prompting the body to release more insulin when blood sugar is high and reducing the release of glucagon, a hormone that raises blood sugar.⁴
Zepbound (tirzepatide): Zepbound is also an injectable medication but it has a dual mechanism of action; it is both a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a GLP-1 receptor agonist. This means it mimics two distinct gut hormones, GIP and GLP-1, both of which are involved in signaling satiety (fullness) and regulating appetite, leading to reduced food intake.⁵ This dual action is a key characteristic that distinguishes Zepbound from GLP-1-only agonists. The engagement of both GIP and GLP-1 pathways is thought to contribute to Zepbound's efficacy, with some head-to-head trial data suggesting it may lead to greater weight loss compared to medications that only target the GLP-1 receptor, like Wegovy.² Understanding this difference can be important, especially if an insurance plan shows a preference for one drug over the other.

Key FDA-Approved Uses in 2025 (Why Your Doctor Prescribed It)

The U.S. Food and Drug Administration (FDA) has approved Wegovy and Zepbound for specific uses, which are critical for insurance coverage considerations.

Wegovy:

Chronic Weight Management: Wegovy is approved for long-term weight reduction and maintenance in adults with obesity (defined as a Body Mass Index, or BMI, of 30 kg/m2 or greater) or in adults who are overweight (BMI of 27 kg/m2 or greater) and also have at least one weight-related medical problem, such as high blood pressure, type 2 diabetes, or high cholesterol. It is also approved for pediatric patients aged 12 years and older who have obesity (defined as an initial BMI at the 95th percentile or greater for their age and sex).¹
Cardiovascular Risk Reduction (Approved March 2024): A significant label expansion for Wegovy includes its use to reduce the risk of major adverse cardiovascular events (MACE), such as heart attack, stroke, or death from cardiovascular causes, in adults who have established cardiovascular disease and are also living with either obesity or overweight.¹ This approval was based on the SELECT trial, which showed Wegovy significantly reduced MACE risk by 20% compared to placebo.¹⁰

Zepbound:

Chronic Weight Management: Zepbound is approved for long-term weight reduction and maintenance in adults with obesity (BMI ≥30 kg/m2) or in adults who are overweight (BMI ≥27 kg/m2) and have at least one weight-related comorbid condition.⁷
Obstructive Sleep Apnea (Approved December 20, 2024): Zepbound received FDA approval as the first drug treatment option for adults with moderate to severe obstructive sleep apnea (OSA) who also have obesity.²

These expanded indications for conditions beyond weight loss alone, such as cardiovascular risk reduction for Wegovy and OSA for Zepbound, can be particularly important when seeking insurance coverage. While these new approvals provide stronger arguments for medical necessity, they do not automatically guarantee coverage if an insurance plan has a broad exclusion for "weight loss" medications. Some insurers may choose to cover these drugs only if the primary reason for prescribing is the expanded indication (e.g., heart disease or OSA), rather than obesity itself.² This means that for patients with both obesity and one of these comorbidities, it's crucial for healthcare providers to be precise with diagnosis codes and clearly link the prescription to the indication that is covered by the patient's specific insurance plan, especially if obesity treatment as a standalone diagnosis is excluded.

A Quick Look at Effectiveness and What to Expect

Both Wegovy and Zepbound have demonstrated significant effectiveness in promoting weight loss when used as prescribed. As mentioned, clinical trial evidence suggests Zepbound may lead to a greater percentage of weight loss compared to Wegovy, potentially due to its dual-hormone action.²

It's important for patients to understand that these medications are intended to be used as part of a comprehensive weight management plan that includes a reduced-calorie diet and increased physical activity.⁷ Weight loss with these treatments is typically a gradual process, and it may take several weeks or even months to observe significant changes in body weight.⁴

The dosage for both Wegovy and Zepbound is usually started at a low level and then gradually increased over a period of weeks or months.⁷ This dose-escalation schedule is designed to help the body adjust to the medication and to minimize potential gastrointestinal side effects.

Important Safety Information to Discuss with Your Doctor

Like all medications, Wegovy and Zepbound have potential side effects and risks that should be discussed with a healthcare provider. Common side effects for both medications include gastrointestinal issues such as nausea, diarrhea, vomiting, constipation, and abdominal pain.¹¹

There are also more serious, though less common, risks associated with these drugs:

Possible Thyroid Tumors, including Medullary Thyroid Carcinoma (MTC): Both Wegovy and Zepbound carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies. It is not known if they cause these tumors in humans. These medications should not be used by individuals with a personal or family history of MTC or by those with an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).¹
Pancreatitis (inflammation of the pancreas): This is a serious potential side effect. Patients should seek immediate medical attention if they experience severe abdominal pain that doesn't go away, with or without vomiting.¹
Gallbladder Problems: Issues such as gallstones or inflammation of the gallbladder can occur, sometimes requiring surgery.¹
Hypoglycemia (low blood sugar): The risk of low blood sugar is increased, particularly if these medications are taken concurrently with other medications used to treat type 2 diabetes, such as insulin or sulfonylureas.³
Other Potential Risks: These can include kidney problems (especially with dehydration from vomiting or diarrhea), severe stomach problems, serious allergic reactions, changes in vision (particularly in patients with type 2 diabetes), increased heart rate, and depression or suicidal thoughts or behaviors.¹ Patients should also inform their provider if they are scheduled for surgery requiring anesthesia, as these drugs can delay gastric emptying.¹

A thorough discussion of individual medical history and potential risks with a healthcare provider is essential before starting either Wegovy or Zepbound. This not only ensures patient safety but also reinforces the medical necessity of these treatments, which can be a factor in insurance discussions.

Supply Status in 2025

The availability of these medications has been a concern in the past, but the situation has improved.

Wegovy: As of early 2025, Wegovy is reported to be in full supply. Novo Nordisk, the manufacturer, has been working to expand patient access, including collaborations with telehealth providers and the establishment of NovoCare® Pharmacy for direct-to-patient shipments.¹
Zepbound (tirzepatide): Tirzepatide (the active ingredient in Zepbound and Mounjaro) was removed from the FDA's drug shortage list in October 2024.² This development has significant implications, as it means that compounded versions of tirzepatide, which some patients may have used during periods of shortage, are no longer permitted by the FDA to be produced by compounding pharmacies as of early 2025.²

The resolution of widespread shortages for both Wegovy and Zepbound shifts the primary challenge for patients from simply finding the medication to affording it and securing formal insurance approval. With compounded alternatives becoming restricted, more individuals who previously relied on them will now need to navigate the official channels for obtaining FDA-approved products. This increases the importance of understanding prior authorization and appeal processes. Furthermore, the availability of "cash-pay" options, such as Wegovy offered at $499 per month through NovoCare® Pharmacy for those without insurance coverage ¹, becomes a more pertinent consideration for individuals who cannot obtain insurance approval but still wish to use the authentic, FDA-approved medication.

Table 1: Wegovy vs. Zepbound at a Glance (2025)

To help summarize the key features of these two medications, the following table provides a quick comparison:

Feature	Wegovy (semaglutide)	Zepbound (tirzepatide)
How it Works (Mechanism)	GLP-1 receptor agonist; mimics one gut hormone to regulate appetite and food intake.3	Dual GIP and GLP-1 receptor agonist; mimics two gut hormones to regulate appetite and food intake.5
Primary FDA-Approved Use	Chronic weight management in adults with obesity or overweight with comorbidities; pediatric patients (12+) with obesity.9	Chronic weight management in adults with obesity or overweight with comorbidities.7
Additional FDA-Approved Uses	Reduction of major adverse cardiovascular event risk in adults with established CVD and obesity/overweight.1	Treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.2
Typical Dosing Schedule	Once-weekly subcutaneous injection; dose typically starts at 0.25 mg and escalates every 4 weeks to a maintenance of 1.7 mg or 2.4 mg.9	Once-weekly subcutaneous injection; dose typically starts at 2.5 mg and escalates every 4 weeks to a maintenance of 5 mg, 10 mg, or 15 mg.7
Reported Average Weight Loss	Significant weight loss.	Significant weight loss; head-to-head trial suggested potentially greater weight loss than Wegovy.2
Common Prior Authorization Triggers	BMI ≥30 or ≥27 with comorbidity; documented lifestyle program; step therapy may be required; specific criteria for CV risk indication.10	BMI ≥30 or ≥27 with comorbidity; documented lifestyle program; step therapy may be required; specific criteria for OSA indication.2

This table offers a snapshot to help patients understand the basic differences and similarities, which can be useful in discussions with healthcare providers and when trying to understand insurance preferences.

The Big Question: Will My Insurance Cover It in 2025?

Understanding whether insurance will cover Wegovy or Zepbound is often the most pressing concern for patients. The answer is complex and depends heavily on the individual's insurance plan.

First, Know Your Plan: Decoding Your Insurance Policy

The first step in determining coverage is to thoroughly understand the specifics of one's own health insurance policy.

The Formulary is Your Friend (Usually): A health plan's formulary is its official list of covered prescription drugs.²¹ Patients can typically find their plan's formulary on the insurer's website, through the member portal, or by calling the customer service number on their insurance card. It is crucial to check if Wegovy or Zepbound is listed. However, even if a medication is on the formulary, it doesn't guarantee coverage without restrictions; prior authorization or step therapy may still be required.²²
Beyond the Formulary: Patients should also review other sections of their policy documents, such as "covered benefits," "exclusions" (especially for weight loss treatments), "prior authorization requirements," and "step therapy rules".²² These sections provide critical details about what the plan will and will not cover, and under what conditions.
Understanding Your Costs: If the drug is covered, it's important to understand the out-of-pocket expenses. This includes the plan's annual deductible (the amount paid before insurance starts covering costs), copayments (a fixed fee per prescription), and coinsurance (a percentage of the drug's cost the patient pays).²³

This foundational knowledge about one's own insurance plan is essential before attempting to get these medications covered, as it dictates the specific rules and hurdles that will need to be addressed.

The 2025 Coverage Landscape: What Are the Trends?

The insurance coverage landscape for GLP-1 agonists like Wegovy and Zepbound remains dynamic and varies significantly across different types of insurance plans.

Commercial/Employer Plans:

For many individuals with commercial or employer-sponsored health insurance, obtaining coverage for these medications continues to be challenging. In 2025, a large majority—over 83% of those with Zepbound coverage and 83% of those with Wegovy coverage—still face restrictions such as prior authorization or step therapy requirements.²⁶
While more than half (52%) of employers reported covering GLP-1s for weight loss, many are implementing cost-containment strategies. These include requiring participation in lifestyle modification programs (reported by 69% of employers covering these drugs), mandating that patients try lower-cost medications first (63%), or limiting the duration of therapy (63%).²⁷ Alarmingly for patients, 14% of employers covering these drugs are considering discontinuing coverage altogether due to the high costs.²⁷
Paradoxically, despite the high demand and proven benefits, the number of individuals with no commercial insurance coverage for Zepbound actually saw an increase in 2025.²⁶ This underscores the financial pressures these drugs place on insurance plans and employers.

ACA Marketplace Plans:

Coverage for Wegovy and Zepbound under plans purchased through the Affordable Care Act (ACA) marketplace can vary widely. The decisions made by Pharmacy Benefit Managers (PBMs) have a substantial impact on which drugs are included in the formularies of these plans and at what cost.
For example, CVS Caremark's decision to give Wegovy preferred status on its standard formulary starting in mid-2025 could make Zepbound more expensive or potentially not covered for many ACA plan members whose plans utilize that PBM.²⁸
Furthermore, some major insurers, such as Aetna, announced plans to exit ACA marketplaces in several states in 2025 due to financial losses, which could reduce the number of plan options available to consumers in those areas.²⁸ This highlights how PBM formulary decisions and insurer participation in marketplaces directly affect patient access and out-of-pocket costs for these medications.

Medicare (for beneficiaries aged 65+ or with certain disabilities):

The general rule for Medicare is that Part D (the prescription drug benefit) is legally prohibited from covering drugs when they are used solely for weight loss or weight management.³³ A proposal in 2024 to change this rule and allow Medicare coverage for obesity as a chronic condition was officially dropped in early 2025.³³
The Exceptions are Key: Despite the general exclusion for weight loss, Medicare Part D plans may cover these medications if they are prescribed for other FDA-approved indications that are considered medically necessary and are not primarily for weight loss.
For Wegovy, this means potential coverage if it is prescribed to reduce cardiovascular risk in patients who have established cardiovascular disease (CVD) along with obesity or overweight, thanks to its 2024 FDA label expansion for this use.¹⁰
For Zepbound, this means potential coverage if it is prescribed for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, following its FDA approval for this indication in December 2024.²
This distinction is critical for Medicare beneficiaries. Access to these drugs under Medicare largely hinges on whether the patient has these specific co-existing conditions (CVD for Wegovy, OSA for Zepbound) and whether the prescription is written primarily for that comorbidity. Two Medicare patients with similar degrees of obesity could face vastly different coverage scenarios based solely on the presence of these additional diagnoses. This underscores the importance of thorough medical evaluation and precise documentation by healthcare providers when seeking coverage for Medicare patients, and it also points to a potential inequity in access for Medicare beneficiaries whose primary or sole diagnosis related to these drugs is obesity.

Medicaid (for eligible low-income individuals):

Medicaid coverage for Wegovy and Zepbound for weight loss is highly inconsistent and varies significantly from state to state.³⁹
As of March 2025, only a handful of states (nine states) provided coverage for GLP-1 agonists for weight loss under their Medicaid programs.³⁹ Some states have considered or implemented expansions (e.g., Colorado), but these are often subject to intense budgetary scrutiny and potential rollbacks due to the high cost of the medications.¹⁶
State Medicaid programs that do offer coverage may impose strict prior authorization criteria, including step therapy. For example, MassHealth (Massachusetts Medicaid) and the UnitedHealthcare Community Plan of Massachusetts implemented policies for 2025 requiring new Zepbound users (adults) to first try and fail treatment with phentermine (a less expensive weight loss medication) before Zepbound would be considered for coverage.²⁰
The newer FDA-approved indications (cardiovascular risk reduction for Wegovy and OSA for Zepbound) might influence some state Medicaid coverage decisions, but the significant budget impact of these drugs remains a primary concern for state programs.³³ Patients covered by Medicaid must check their specific state's Medicaid formulary and coverage policies.

The Powerful Influence of PBMs (Pharmacy Benefit Managers)

Pharmacy Benefit Managers (PBMs) are companies that manage prescription drug benefits on behalf of health insurers, Medicare Part D plans, large employers, and other payers. They play a crucial, though often invisible to the patient, role in determining drug accessibility and cost.⁴¹ PBMs negotiate with pharmaceutical manufacturers to obtain discounts and rebates, and they develop and manage formularies (lists of covered drugs).⁴¹

These formulary decisions, which dictate whether a drug is "preferred," "non-preferred," or "not covered," are often heavily influenced by the net cost to the PBM and the health plan after rebates, rather than solely by clinical effectiveness.⁴² A clear example of this influence in 2025 is the decision by CVS Caremark, one of the largest PBMs, to designate Wegovy as a preferred GLP-1 medication for weight loss on its standard commercial template formularies, effective July 1, 2025.²⁸ This move means that for the tens of millions of Americans whose drug benefits are managed by this PBM formulary, Wegovy will likely be easier to access and have lower out-of-pocket costs compared to Zepbound. Conversely, Zepbound may become non-preferred or even excluded, leading to higher costs or outright denials for patients whose plans follow this formulary.²⁹ Patients currently taking Zepbound under such plans might be asked by their insurer or PBM to switch to Wegovy.²⁹

This situation illustrates how PBM decisions can effectively override a physician's clinical choice of medication or create significant access hurdles for patients. Even if a doctor prescribes Zepbound, believing it to be clinically superior for a particular patient (perhaps based on data suggesting greater weight loss ²), the patient may find it denied or prohibitively expensive simply due to their PBM's contractual arrangements. This makes it essential for patients and their doctors to be aware of the patient's specific PBM formulary and to be prepared to appeal for a non-preferred drug if there is a strong medical justification.

Prior Authorization: Your First Hurdle (and How to Clear It)

For most patients seeking Wegovy or Zepbound, prior authorization (PA) is an unavoidable first step in the insurance approval process.

What is Prior Authorization (PA) and Why is it Almost Always Required?

Prior authorization is a process used by insurance companies to review certain prescription medications, medical procedures, or services before they agree to cover them.¹⁹ Essentially, the insurer requires the prescribing healthcare provider to submit additional clinical information to demonstrate that the requested medication is medically necessary and appropriate for the patient's specific condition, according to the insurer's criteria.

For medications like Wegovy and Zepbound, PA is almost universally required due to several factors, primarily their high cost and the need to ensure they are being used appropriately according to their FDA-approved indications and the health plan's specific coverage rules.¹⁹ Insurers use PA as a tool to manage costs and to prevent inappropriate prescribing.

Common Prior Authorization Requirements for Wegovy & Zepbound in 2025

While specific PA criteria can vary from one insurance plan to another, several common requirements have emerged for Wegovy and Zepbound in 2025:

BMI Thresholds: Insurers typically require patients to meet certain Body Mass Index (BMI) criteria. Commonly, this is a BMI of 30 kg/m2 or higher (classified as obesity), or a BMI of 27 kg/m2 or higher (classified as overweight) if the patient also has at least one qualifying weight-related comorbidity.¹⁰ Examples of such comorbidities include hypertension (high blood pressure), type 2 diabetes, dyslipidemia (abnormal cholesterol levels), obstructive sleep apnea (OSA), or established cardiovascular disease (CVD).
Specific Comorbidities (especially for certain plans or indications):
For Wegovy, if coverage is sought based on its cardiovascular risk reduction indication (particularly relevant for Medicare plans or plans that exclude weight loss alone), documented proof of established cardiovascular disease is necessary.¹⁰
For Zepbound, if coverage is sought based on its obstructive sleep apnea indication, documentation of moderate to severe OSA (often confirmed by a sleep study) is required.²
Documented Lifestyle Changes: Most plans require evidence that the patient has actively participated in, or is concurrently enrolled in, a comprehensive lifestyle modification program. This typically includes a reduced-calorie diet and increased physical activity, often for a specified duration (e.g., 3 to 6 months) prior to or alongside the medication request.¹⁹ Some plans, like one from Express Scripts, may even require enrollment in a specific Diabetes Prevention Program.⁴⁸
Step Therapy (Failing First): A very common requirement is "step therapy," where the patient must have tried and "failed" (meaning the drug was not effective enough or caused intolerable side effects) one or more alternative, usually less expensive, weight management medications before Wegovy or Zepbound will be approved.²⁰
The specific drugs required in step therapy vary by plan but can include older weight loss medications like phentermine, Qsymia, Contrave, or Orlistat. Depending on the PBM's preferred drug list, some plans might even require a trial of the other GLP-1 agonist (e.g., trying Wegovy before Zepbound, or vice versa).
For example, in 2025, both MassHealth and UnitedHealthcare Community Plan of Massachusetts began requiring new adult users of Zepbound to first try phentermine.²⁰
Exclusion of Certain Conditions: PA criteria will often include checks to ensure the patient does not have conditions that are contraindicated for the medication. For both Wegovy and Zepbound, this includes a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).¹ For Zepbound, it may also include an exclusion if the patient has a history of pancreatitis, as it was not studied in this population.¹²
Requirements for Re-authorization: Initial PA approvals are usually time-limited (e.g., 6 months or 1 year). To continue coverage, a re-authorization request is needed. This typically requires documentation of successful weight loss (e.g., at least 5% of the starting body weight) and continued adherence to lifestyle modifications.⁴³

Understanding these common PA hurdles is the first step in preparing a strong case for approval.

Partnering with Your Doctor: The Key to PA Success

The prior authorization process is a collaborative effort between the patient and their healthcare provider, with the provider's office typically taking the lead in submitting the required forms and documentation to the insurance company.¹⁹

Information your doctor will need to provide: The PA request will require detailed clinical information, including:
The patient's specific diagnosis (e.g., obesity, overweight with comorbidities) with the corresponding International Classification of Diseases (ICD-10) codes.
Current and baseline BMI.
Detailed documentation of any relevant comorbidities (e.g., hypertension, type 2 diabetes, OSA, CVD), including diagnostic codes and supporting clinical notes or test results.
A comprehensive history of previously attempted weight loss methods. This includes specific diets, exercise programs, and any prior weight loss medications tried. For each medication, the doctor will need to list the name, dosage, duration of use, the outcome (e.g., amount of weight lost, if any), and the reason for discontinuation (e.g., lack of efficacy, intolerable side effects).²¹
What you need to provide to your doctor: To help the doctor complete the PA accurately and thoroughly, patients should provide:
A complete and accurate medical history.
A detailed list of all previous weight loss attempts. This includes the names of specific diets followed (e.g., Atkins, Mediterranean), participation in commercial weight loss programs (like Weight Watchers or Noom – if possible, provide receipts, check-in records, or other proof of participation), gym memberships, personal training sessions, and consultations with nutritionists. It's crucial to include approximate dates, duration of these attempts, and the results achieved.²¹
If prior weight loss medications were used, provide the names, dosages, how long they were taken, any side effects experienced, and why they were stopped.

The more detailed and accurate the information provided by the patient, the stronger the PA request submitted by the doctor will be.

"How Do I Prove I Tried Other Things?" – Documenting Step Therapy and Lifestyle Efforts

One of the most common reasons for PA denials is insufficient documentation of having met step therapy requirements or having engaged in adequate lifestyle modification efforts. Here’s how to address this:

Medications: For each alternative medication tried as part of step therapy, the documentation should be precise. This includes the medication name, dosage, start and end dates of the trial, and a clear reason for why it was considered a "failure" or why it was stopped. Examples include: "Patient took phentermine 37.5 mg daily for 3 months, lost only 2 pounds, deemed ineffective," or "Patient attempted Contrave, but experienced intolerable nausea and vomiting, leading to discontinuation after 2 weeks.".²¹ The healthcare provider's contemporaneous medical notes are the best source for this documentation. Some plans may have very specific definitions of "failure," such as not achieving a certain percentage of weight loss within a set timeframe.⁴⁹
Lifestyle Programs: Documenting participation in lifestyle programs requires detail. If commercial programs like Weight Watchers or Noom were used, any available receipts, membership confirmations, or progress reports (e.g., weigh-in logs, food diaries) should be gathered.²¹ For self-directed efforts, list specific diets followed (e.g., Atkins, Mediterranean, calorie-restricted diet of X calories/day), duration of adherence, and outcomes. Mention consultations with nutritionists or dietitians, gym memberships, or periods of consistent personal training, including dates and perceived effectiveness.²¹
Contraindications: If a preferred alternative medication listed in the step therapy protocol is medically contraindicated for the patient (meaning it would be unsafe for them to take due to another medical condition, potential drug interaction, or history of severe adverse reaction), the healthcare provider must clearly document this contraindication and the medical reasoning behind it in the PA submission.²¹ This can allow the patient to "step through" that requirement without actually trying the drug.

Thorough and specific documentation is the key to successfully navigating step therapy requirements.

The Waiting Game: How Long Does PA Take?

The time it takes for an insurance company to process a prior authorization request can vary significantly.

If the request is submitted electronically and all criteria are clearly met, an approval (or denial) might come back almost immediately or within a few hours.⁴³
However, for more complex cases or if manual review is needed, the process can take several business days to a few weeks. For example, some sources indicate that Aetna may take up to 14 days, while Blue Shield of California aims for 24 to 72 hours.⁴⁴ Medicare Part D plans are generally required to provide a decision within 72 hours for standard requests (24 hours for expedited requests if a delay could seriously jeopardize the patient's health).⁴³

If a response is not received within the expected timeframe, it is advisable for the patient or the doctor's office to follow up with the insurance company to check on the status of the request.

Table 2: Common Prior Authorization Requirements Checklist

This checklist can help patients and their doctors prepare for a prior authorization request by ensuring all common requirements are considered and documented.

Requirement	Details Needed	My Information / Doctor's Notes (Patient to fill with doctor)
Diagnosis	Obesity (ICD-10 code E66.--) or Overweight (ICD-10 code E66.3) with specific weight-related comorbidity.
Specific Comorbidity (if applicable)	E.g., Cardiovascular Disease (ICD-10 I25.-- for Wegovy), Obstructive Sleep Apnea (ICD-10 G47.33 for Zepbound), Type 2 Diabetes (E11.--), Hypertension (I10). Document with codes & notes.
Current BMI	Calculated from current height and weight (kg/m2).
Baseline BMI	BMI before starting current comprehensive weight management attempt (kg/m2).
History of Diet & Exercise	Names of specific diet programs (e.g., Weight Watchers, Noom, specific calorie deficit), duration, start/end dates, documented outcomes (weight lost/gained). Exercise regimen.
Previous Weight Loss Medications Tried	For each: Medication Name, Dosage, Start/End Dates, Outcome (e.g., "ineffective - lost X lbs in Y months"), Reason for Discontinuation (e.g., side effects, lack of efficacy).
Contraindications to Preferred Alternatives	If step therapy requires a drug that is unsafe for the patient, list the drug and the specific medical reason/contraindication.
Plan for Ongoing Lifestyle Modification	Confirmation of commitment to continued reduced-calorie diet and increased physical activity.
For Re-authorization: Documented Weight Loss	Percentage of initial body weight lost since starting the medication (e.g., must be ≥5% after X months).

This checklist serves as a proactive tool to gather necessary information, facilitating a more complete and potentially successful prior authorization submission.

"Denied!" – Don't Panic! How to Appeal and Win

Receiving a denial for Wegovy or Zepbound can be incredibly disheartening, but it is often not the final word. Understanding why denials happen and knowing how to effectively appeal the decision can significantly increase the chances of ultimately getting the medication covered.

It’s Not the End of the Road: Why Denials Happen and Why You Should Appeal

Insurance companies may deny coverage for Wegovy or Zepbound for a variety of reasons. It's important to remember that an initial denial, especially for high-cost medications, is quite common.

Common Reasons for Denial:

"Not Medically Necessary" (according to the insurer): The insurer may determine that, based on the information submitted, the medication is not essential for the patient's condition, that the condition is not severe enough to warrant such an expensive treatment, or that other, less costly treatments should be tried first.¹⁹ This is often a subjective judgment by the insurer and can be countered with strong medical evidence and robust support from the prescribing physician.
Plan Exclusion: Some insurance plans have explicit exclusions for all weight-loss medications, categorizing them as non-essential, cosmetic, or lifestyle choices rather than treatments for a medical condition.¹⁹ While this is a difficult hurdle, appeals can sometimes be successful by arguing the long-term cost savings to the insurer that would result from preventing or managing costly obesity-related comorbidities like heart disease or type 2 diabetes.²¹
Not on Formulary / Formulary Exception Needed: The prescribed medication may simply not be on the insurance plan's list of covered drugs (formulary), or it may be on a non-preferred tier with very high cost-sharing.²¹ In such cases, a formulary exception request is needed, arguing why preferred alternatives are not suitable for the patient.
Failure to Meet Step Therapy Requirements: The denial may state that the patient has not tried and "failed" (or does not have a documented contraindication to) the insurer's preferred alternative medications first.¹⁹
Paperwork Errors or Missing Information: Denials can occur due to simple administrative errors, such as incorrect diagnosis or procedure codes, misspelled names, missing dates of service, or incomplete medical history provided in the initial PA request.²⁵ These are often the easiest types of denials to overturn once the correct information is supplied.
Incorrectly Entered Information Leading to Automated Denial: Many initial PA reviews are handled by automated computer systems. If any information about the patient's BMI, specific health conditions, or medication history is entered incorrectly or does not precisely match the system's programmed criteria, an automatic denial can be generated without human review.⁴⁷

Why Appeal? Success is Possible!

It is crucial for patients not to be discouraged by an initial denial. There are compelling reasons to pursue an appeal:

Appeals Get Human Review: Unlike many initial PA decisions that may be automated, an appeal typically ensures that the case is reviewed by a human being, often a clinician or a medical director at the insurance company.⁴⁷ This allows for a more nuanced consideration of the patient's individual circumstances.
Appeals Can Be Successful: Data suggests that a significant percentage of appeals are successful. Studies and reports indicate that internal appeals to the insurance provider can have success rates ranging from 39% to 59%.⁴⁷ Other research looking at healthcare-related denial appeals more broadly found success rates around 41%.⁴⁵ This means that nearly half of the time, taking the effort to appeal can lead to a reversal of the denial.

Given these factors, appealing a denial is almost always worthwhile if the medication is considered important for the patient's health.

Your Right to Appeal: Understanding the Levels

Patients generally have a legal right to appeal a health insurance company's decision to deny coverage for a prescribed medication, especially if their health plan was created after March 23, 2010, due to protections established by the Affordable Care Act (ACA).¹⁹ The appeals process typically involves several levels:

Internal Appeals: These are reviews conducted by the insurance company itself.
First-Level Internal Appeal: This is the patient's first formal request for the insurer to reconsider its denial. The patient (or their doctor) submits additional information and arguments to support the medical necessity of the medication.⁵¹
Second-Level Internal Appeal (if offered by the plan): Some insurance plans offer an opportunity for a second internal review if the first-level appeal is also denied. This may involve a different set of reviewers within the insurance company.⁵¹
External Review (Independent Medical Review): If all available internal appeals are exhausted and the denial is upheld, the patient typically has the right to request an external review.⁴³ This review is conducted by an independent third-party organization (an Independent Review Organization, or IRO) that is not affiliated with the insurance company. The IRO's decision is usually legally binding on the insurer.

Clearly understanding these distinct stages of the appeals process can help patients and their advocates prepare for each step and know what to expect.

Step-by-Step Guide to Filing a Winning Internal Appeal

Successfully appealing an insurance denial requires a methodical approach, careful preparation, and strong collaboration with the prescribing healthcare provider.

1. Understand Your Denial Letter (Explanation of Benefits - EOB):
When an insurer denies a prior authorization request, they are legally required to provide a written explanation for the denial. This is often found in a document called the Explanation of Benefits (EOB) or a separate denial letter.¹⁹
This document is the starting point for an appeal. It should clearly state the exact reason(s) why coverage was denied. Carefully analyze these reasons, as the appeal must directly address each point. For instance, did the insurer say the BMI was not high enough, that step therapy was not completed, or that the medication is a plan exclusion?
The denial letter will also specify the deadline for filing an appeal. For private insurance plans, this is often 180 days (or 6 months) from the date of the denial notice.¹⁹ It's crucial to adhere to this deadline.
2. Gather Your Evidence – Build Your Case:
This is where teamwork with the doctor becomes absolutely critical.¹⁹ The appeal needs to be supported by robust medical evidence.
Letter of Medical Necessity (LMN) from Your Doctor: This is arguably the most important document in an appeal. It is a detailed letter written by the prescribing physician explaining why this specific medication (Wegovy or Zepbound) is medically necessary for this particular patient. The LMN should:
Directly address the reasons stated in the denial letter.
Provide a summary of the patient's relevant medical history, including their diagnosis of obesity/overweight, their BMI, and any significant comorbidities (e.g., hypertension, type 2 diabetes, cardiovascular disease, obstructive sleep apnea).
Detail all previous attempts at weight management, including specific diets, exercise programs, and prior weight loss medications (names, dosages, duration of use, outcomes, and reasons for discontinuation, such as lack of efficacy or intolerable side effects).
Explain why alternative treatments (especially those preferred by the insurer) are not appropriate or have already failed for this patient.
Highlight any unique patient factors that make the prescribed medication the most suitable option.
If the patient has already started the medication (e.g., through samples or self-pay) and has experienced positive results (e.g., weight loss, improvement in lab markers, better AHI scores for OSA), this should be strongly emphasized.²¹
The LMN may also reference relevant clinical practice guidelines (e.g., from the Obesity Medicine Association ⁵⁴) or peer-reviewed scientific studies that support the use of the medication for the patient's specific condition or to prevent obesity-related complications.⁸ For example, citing the SELECT trial for Wegovy's cardiovascular benefits ¹⁰ or the SURMOUNT-OSA trials for Zepbound's efficacy in sleep apnea ² can be powerful.
Drug manufacturers often provide templates or guidance for LMNs (e.g., Eli Lilly for Zepbound ⁵⁰, Novo Nordisk for Wegovy ¹⁹), which can be helpful starting points for the doctor.
Supporting Medical Records: Include copies of relevant portions of the patient's medical record, such as:
Physician's chart notes documenting the diagnosis, progression of the condition, and treatment plan.
Recent lab results (e.g., HbA1c, lipid panels, liver function tests).
For OSA, sleep study reports. For CVD, cardiology notes or test results.
Records of weigh-ins and BMI calculations over time.²¹
Documentation of Tried/Failed Therapies: Provide detailed records of all previous weight loss efforts, as outlined in the PA section. The more specific and well-documented this history, the stronger the argument that other options have been exhausted.¹⁹
3. Writing a Powerful Appeal Letter (You or Your Doctor):
While the LMN from the doctor is central, the patient may also write a cover letter for the appeal, or the doctor's office may prepare the entire appeal package. The appeal letter should be clear, factual, and persuasive.
Key Elements to Include:
Patient's full name, insurance policy number, and claim or case number from the denial letter.¹⁹
Date of the denial letter and a clear statement that this is an appeal of that decision.
A concise summary of the reason(s) for denial as stated by the insurer.
A point-by-point rebuttal of each denial reason, referencing the enclosed LMN and supporting medical records.
If the denial was due to the drug not being on formulary, formally request a formulary exception and explain why preferred alternatives are not medically appropriate (e.g., tried and failed, contraindications, or evidence suggesting the prescribed drug is significantly more effective for the patient's specific profile – for instance, if Zepbound is denied but evidence suggests it may be more effective than a preferred GLP-1 like Wegovy for that patient ²).
If the denial was due to a plan exclusion for weight loss, but the patient has a relevant comorbidity for which the drug has an FDA-approved indication (e.g., CVD for Wegovy, OSA for Zepbound), emphasize this and argue that the prescription is for treating that comorbidity, which also happens to address weight. Alternatively, argue the long-term cost-effectiveness of treating obesity to prevent more expensive future health complications.²¹
Clearly explain the anticipated positive impact of the medication on the patient's health, daily functioning, and quality of life.¹⁹
Maintain a professional and respectful tone throughout the letter, even if feeling frustrated.
Clearly list all enclosed documents (e.g., "Enclosed please find: Letter of Medical Necessity from Dr. X, relevant chart notes, lab results from [date], etc.").
Sample Letters: As mentioned, drug manufacturers (Wegovy ¹⁹, Zepbound ⁵⁰) and patient advocacy groups like the Obesity Action Coalition ²³ often provide sample appeal letters or templates that can be adapted.
4. The Peer-to-Peer Review: Your Doctor's Chance to Advocate Directly:
In some cases, either before a formal written appeal is submitted or as part of the appeal review process, the insurance company may offer (or the prescribing doctor can request) a "peer-to-peer" review.¹⁹
This involves a direct telephone conversation between the prescribing physician and a medical reviewer (a physician or pharmacist) employed by or contracted with the insurance company.
This is a valuable opportunity for the patient's doctor to verbally explain the clinical rationale for the prescription, answer any questions the insurer's reviewer may have, and advocate directly for the patient. Sometimes, a peer-to-peer discussion can lead to an overturned denial without the need for a full written appeal process, or it can clarify what specific additional information is needed for approval.
5. Submitting Your Appeal:
It is crucial to follow the insurance company's specific instructions for submitting an appeal. These instructions are usually found in the denial letter or on the insurer's website. Appeals may need to be sent by mail, fax, or through an online member portal.¹⁹
If submitting by mail, it is highly recommended to use certified mail with a return receipt requested to have proof of delivery.⁵¹ If submitting by fax or online portal, keep a copy of the transmission confirmation.
Always keep complete copies of everything submitted to the insurance company for the patient's records.
6. Follow Up, Follow Up, Follow Up!
Submitting the appeal is not the final step. It is important to proactively follow up with the insurance company.¹⁹
A few days after submitting, call the insurer to confirm that the appeal was received and is being processed.
Inquire about the expected timeline for the review and when a decision can be anticipated. Insurers usually have specific timeframes within which they must respond to appeals (e.g., 30 days for non-urgent pre-service appeals, though this can vary).
Polite persistence can help ensure the appeal receives timely attention and is not overlooked.¹⁹

Escalating to an External Review: When Your Insurer Still Says No

If all available internal appeals with the insurance company have been exhausted and the denial is still upheld, patients usually have the right to request an external review, also known as an Independent Medical Review (IMR).⁴³

What is it? An external review is an appeal to an independent, third-party organization (an Independent Review Organization or IRO) that is not affiliated with the insurance company. The IRO will review all the medical information from the patient, the doctor, and the insurance company to make an impartial decision about whether the denied service or medication is medically necessary and should be covered.
Who handles it? The process for external review varies depending on the state and the type of health plan (e.g., fully insured vs. self-funded employer plan).
Many states have their own external review processes that meet or exceed federal consumer protection standards. In these states, the state's designated agency or contracted IROs will handle the review.⁵³
If a state does not have an external review process that meets minimum federal standards, or for certain types of plans (like many self-funded employer plans governed by ERISA), the U.S. Department of Health and Human Services (HHS) may oversee an external review process. This is often administered by a contracted entity, such as MAXIMUS Federal Services.⁴³
The final denial letter from the insurance company (after internal appeals) should provide information on how to request an external review and which entity will conduct it.
How to request an external review: The patient must typically file a written request for an external review within a specific timeframe after receiving the final denial from the insurer (e.g., within 4 months according to HealthCare.gov for some federal processes ⁵³). The denial letter should provide instructions. For the HHS-Administered Federal External Review Process, requests can often be submitted online (e.g., via externalappeal.cms.gov), by phone (to request a form), by fax, or by mail.⁴³
Timeline for decision: Standard external reviews are typically decided within 45 days after the request is received. Expedited external reviews (if the patient's health is in jeopardy due to a delay) are usually decided much faster, often within 72 hours or less.⁵³
Cost: For external reviews under the HHS-Administered Federal process, there is generally no charge to the patient. If a state external review process is used, or if the insurer contracts directly with an IRO for a self-funded plan, there might be a small filing fee (e.g., not more than $25 in some cases).⁵³
Binding Decision: A key feature of external review is that the IRO's decision is legally binding on the health insurance company.⁵³ If the external reviewer decides in the patient's favor, the insurer must cover the medication or service.

The external review process provides an important avenue for an impartial decision when disagreements persist between the patient/doctor and the insurance company.

Table 3: Insurance Denial Appeal Stages & Key Actions

The following table summarizes the typical stages of an insurance denial appeal, who conducts the review, general timelines, and key actions for the patient and doctor.

Appeal Stage	Who Reviews?	Typical Timeline for Decision	Key Patient/Doctor Actions	Potential for Success
Initial Denial (PA Denied)	Insurance Company (often automated/initial reviewer)	Varies (hours to weeks)	Patient: Notify doctor. Doctor: Review denial, discuss with patient.	N/A (This is the decision being appealed)
First-Level Internal Appeal	Insurance Company (internal appeals department)	~30-60 days (can vary)	Patient & Doctor: Submit formal appeal letter, comprehensive Letter of Medical Necessity, all supporting medical records, documentation of tried/failed therapies. Address denial reasons.	Moderate (39-59% success reported for internal appeals 47; 41% for general healthcare appeals 45)
Second-Level Internal Appeal (if applicable by plan)	Insurance Company (often different internal reviewers)	~30-60 days (can vary)	Patient & Doctor: Submit any new evidence, reiterate arguments, address reasons for first-level appeal denial.	Varies; may be lower than first-level if no new compelling evidence.
External (Independent) Medical Review	Independent Review Organization (IRO)	~45 days (standard); ~72 hrs (expedited)	Patient & Doctor: Submit all previous documentation and appeal history to the IRO as per their instructions. Ensure all deadlines are met.	Varies, but offers an impartial review. Decision is binding on the insurer.53

This table provides a structured overview of the appeals journey, helping to set expectations and guide actions at each critical phase.

Practical Tips for Managing the Insurance Maze

Navigating the complexities of insurance for high-cost medications like Wegovy and Zepbound requires organization, effective communication, and knowing where to turn for help.

Become a Paperwork Pro: Organizing Your Documents

Keeping meticulous records is crucial when dealing with insurance issues, especially if an appeal becomes necessary.

Create a Dedicated System: Establish a physical binder or a secure digital folder specifically for all documents related to Wegovy or Zepbound coverage.
What to Keep:
Copies of the patient's insurance card (front and back).
The full insurance policy document, including the summary of benefits and coverage (SBC), and especially the formulary (drug list) and sections detailing prior authorization and appeal procedures.
All correspondence with the insurance company: This includes prior authorization submission confirmations, denial letters (EOBs), appeal submission confirmations, and any letters or emails exchanged.
Copies of all documents submitted to the insurer: This includes the prior authorization form, the Letter of Medical Necessity (LMN) from the doctor, appeal letters, and all supporting medical records.
Relevant medical records: Chart notes from doctor visits related to weight, obesity, and any associated comorbidities (like cardiovascular disease or sleep apnea), lab test results, sleep study reports, BMI calculations, and documentation of weight history.
Proof of participation in lifestyle modification programs or previous weight loss attempts: Receipts for commercial programs (e.g., Weight Watchers, Noom), gym membership contracts, nutritionist consultation notes, food diaries, and detailed notes on diets tried with dates and outcomes.²¹
Receipts for any out-of-pocket expenses related to the medication or required therapies.
Organization Method: Organize documents chronologically within categories (e.g., "Correspondence with Insurer," "Medical Records Submitted," "Appeal Documentation"). This makes it easier to find specific information when needed.⁶² Some find it helpful to ask for a copy of their insurer's medical policy for obesity treatments, as this outlines the specific criteria they use.⁶³

Well-organized paperwork can make the difference between a confusing, stressful process and a well-prepared, effective appeal.

Communicating Effectively with Your Insurance Company

Clear and documented communication with the insurance company is essential.

Keep a Log: For every phone call with the insurer, note the date, time, the name and department of the person spoken to, and a summary of the conversation, including any reference numbers provided for the call.
Be Polite but Persistent: Maintain a calm and professional demeanor, even when frustrated. Clearly state the purpose of the call and the information needed.
Ask for Clarification: If any information provided by the insurer is unclear (e.g., the reason for a denial, the next steps in an appeal), ask for it to be explained in simple terms. Request information in writing if possible.
Use Secure Channels: When submitting sensitive medical information, use secure methods like the insurer's online portal (if available), fax, or certified mail, rather than unsecured email.

Talking to Your Doctor About Insurance and Cost Concerns

Open communication with the healthcare provider is vital throughout this process.

Discuss Insurance Early: When Wegovy or Zepbound is first prescribed, patients should feel comfortable discussing potential insurance hurdles and costs with their doctor.⁶⁴ The doctor's office may have staff members (e.g., benefits coordinators, PA specialists) who are experienced in navigating these issues and can offer assistance or insights.
Inquire about PA and Appeal Support: Ask the doctor or their staff about their experience with getting these specific medications approved and if they have resources like sample LMNs or established protocols for appeals.⁶⁵
Discuss Alternatives if Denied: If coverage for Wegovy or Zepbound is ultimately denied and appeals are unsuccessful, talk to the doctor about alternative weight management medications that might be covered by the insurance plan or be more affordable.⁶⁴

The doctor is a key partner not only in medical care but also in navigating the administrative aspects of accessing that care.

Leveraging Patient Advocacy Groups and Resources

Patients do not have to navigate this challenging process alone. Several patient advocacy organizations offer invaluable resources, support, and guidance.

Obesity Action Coalition (OAC): The OAC is a leading national non-profit dedicated to supporting individuals affected by obesity. They provide a wealth of resources specifically aimed at helping patients overcome access barriers:
Insurance Navigation Guides: The OAC offers comprehensive guides on "Working with Your Insurance Provider" and "Working with Your Employer" to understand policies and advocate for coverage.⁶⁰
Sample Letters: They provide templates for appeal letters and letters to employers requesting coverage for obesity treatments.²³
Information on State Resources: Guidance on how to contact State Departments of Insurance to file complaints or share access challenges.⁶⁰
Legislative Advocacy Tools: Resources to help patients contact their state and federal elected officials to advocate for better obesity care coverage and policies.⁶⁰
Community Support: The OAC hosts community discussion forums and events like the "Your Weight Matters" National Convention, providing opportunities for peer support and education.⁶⁷
Other Professional Organizations: While primarily focused on healthcare professionals, organizations like The Obesity Society (TOS) ⁷¹, the American Society for Metabolic and Bariatric Surgery (ASMBS) ⁶⁶, the Obesity Medicine Association (OMA) ⁵⁴, and the American Board of Obesity Medicine (ABOM) ⁷⁵ publish clinical guidelines, research, and position statements that can sometimes be used to support the medical necessity arguments in appeals. They also contribute to the broader understanding and recognition of obesity as a serious chronic disease requiring comprehensive treatment.

These advocacy groups serve as crucial navigators, translating the complex world of insurance and healthcare policy into patient-friendly language and actionable strategies. They also amplify individual voices by advocating for systemic changes to improve access to care and reduce the stigma associated with obesity. Tapping into their resources can provide not only practical assistance for individual appeals but also connect patients to a larger community and movement for change.

Lowering Costs: Savings Programs and Other Financial Help

Even if insurance coverage is obtained, out-of-pocket costs for Wegovy and Zepbound can be substantial. If coverage is denied, the full cost can be prohibitive for many. Fortunately, manufacturers offer savings programs, and other avenues for financial assistance may be available.

Wegovy Savings Options (2025)

Novo Nordisk, the manufacturer of Wegovy, offers several programs to help patients with the cost:

NovoCare® Savings Offer:
For patients with commercial insurance that covers Wegovy: Eligible patients may pay as little as $0 per 28-day supply (1 box). This offer is subject to a maximum monthly savings of $225 and can be used for up to 13 fills.⁷⁷
For patients with commercial insurance that does not cover Wegovy, or for uninsured/cash-paying patients: Novo Nordisk has introduced an option to purchase Wegovy for $499 per month for all dose strengths.¹ This can be accessed through NovoCare® Pharmacy or, as of March 2025, also at local pharmacies participating in the "Beyond NovoCare Pharmacy" program.¹⁵ It is important to note that when using this $499 offer, the prescription is processed outside of insurance, meaning the cost will not count toward the patient's insurance deductible or annual out-of-pocket maximum.⁷⁷ Some sources also mention a $650 per month cash option.⁷⁷
NovoCare® Pharmacy: This is a direct-to-patient pharmacy service that facilitates convenient home delivery of Wegovy, particularly for those utilizing the $499 cash-pay program.¹ Telehealth providers like LifeMD are also integrating with NovoCare® Pharmacy to offer this pathway to their cash-pay patients.⁷⁹
WeGoTogether® Support Program: This is a free program offering personalized support to Wegovy users, including access to a health coach, a personal web portal for progress tracking, medication reminders, and motivational tips. This support is available even to patients who are not eligible for the savings offer.⁷⁷
Eligibility and Exclusions: The Wegovy savings offers are generally available to patients with commercial insurance. Patients covered by government-funded healthcare programs (such as Medicare, Medicaid, VA, DoD, TRICARE) are typically excluded from these manufacturer savings programs.⁷⁷ All offers are subject to terms and conditions, and Novo Nordisk reserves the right to modify or cancel them at any time.⁷⁷

The $499 cash price through NovoCare® Pharmacy and its expansion represents a significant development for individuals without insurance coverage, making the authentic medication more accessible than the previous list price, though still a considerable monthly expense for many.

Zepbound Savings Options (2025)

Eli Lilly and Company, the manufacturer of Zepbound, also provides a savings card program:

Lilly Zepbound Savings Card: The terms of this program have been extended through December 31, 2025.⁸²
For patients with commercial insurance that covers Zepbound: Eligible patients may pay as little as $25 for a 1-month, 2-month, or 3-month supply. The card provides a maximum monthly savings of $150 for a 1-month prescription, $300 for a 2-month prescription, or $450 for a 3-month prescription. The maximum annual savings is $1,950, and the card can be used for up to 13 prescription fills per calendar year.⁸²
For patients with commercial insurance that does not cover Zepbound: Eligible patients can obtain savings of up to $569 off their 1-month prescription fill. The maximum annual savings under this part of the program is $7,397, and it can be used for up to 13 fills per calendar year.⁸²
There has been some variation reported based on when a patient initially activated their "no coverage" card. Patients who enrolled before August 28, 2024, were reportedly offered a price as low as $550 per month, while those activating on or after that date were on a "pay as little as $650" version (reflecting a lower maximum monthly saving from Lilly).⁸² The $569 maximum monthly saving for those without coverage appears to be the most current general offer from Lilly for 2025.
Zepbound Self Pay Journey Program: For Zepbound vials (7.5 mg and 10 mg doses only), Lilly offers a program where patients can pay $499 per month if they refill their prescription within 45 days of the previous delivery. This program began February 25, 2025.⁸⁴
Eligibility and Exclusions: The Zepbound Savings Card is for patients with commercial drug insurance and is not available to those enrolled in state, federal, or government-funded healthcare programs (e.g., Medicare, Medicaid).⁸³ The prescription must be for an FDA-approved use. Patient HIPAA authorization is required. A significant exclusion is for patients whose insurance plans participate in "alternate funding programs" (AFPs) that require patients to apply to manufacturer savings programs as a condition of coverage; these patients are not eligible for the Zepbound Savings Card.⁸³ The card is also not valid for Massachusetts residents if an AB-rated generic equivalent is available, or for California residents if an FDA-approved therapeutic equivalent is available.⁸³

Table 4: Wegovy & Zepbound Manufacturer Savings Programs Quick Guide (2025)

This table provides a simplified comparison of the primary savings programs offered by the manufacturers. Patients should always refer to the full terms and conditions on the manufacturers' websites for the most current and complete details.

Program Feature	Wegovy Savings Offer (Novo Nordisk)	Zepbound Savings Card (Eli Lilly)
Eligibility (Commercial with Coverage)	Yes 77	Yes 83
Cost with Coverage (as low as)	$0 per month (28-day supply) 77	$25 per 1-3 month supply 83
Max Monthly Savings (with coverage)	$225 per 28-day supply 77	$150 (1-mo), $300 (2-mo), $450 (3-mo) 83
Max Annual Savings (with coverage)	Max 13 fills, implies up to $2925 ($225x13) but check terms.	$1,950 83
Eligibility (Commercial w/o Coverage or Cash Pay)	Yes (Commercial w/o coverage, or uninsured/cash-pay) 77	Yes (Commercial w/o coverage) 83
Cost without Coverage (as low as)	$499 per month (28-day supply) via NovoCare Pharmacy / participating pharmacies. Processed outside insurance.1 (Also a $650/mo option mentioned 77). $499/mo for vials (7.5mg, 10mg).84	Approx. $550-$650 per month (28-day supply), depending on enrollment date and specific offer terms. Processed with max saving of $569/mo.82
Max Annual Savings (without coverage)	Not explicitly stated as annual cap for $499 offer, but implies consistent monthly price.	$7,397 83
Key Exclusions	Governmental beneficiaries (Medicare, Medicaid, VA, etc.).77	Governmental beneficiaries; plans with Alternate Funding Programs; MA (if AB-generic available), CA (if therapeutic equivalent available).83
Expiration Date (for 2025 offers)	Program can be modified/cancelled by Novo Nordisk at any time.77 Check website for current status.	December 31, 2025.82

While these manufacturer savings programs can provide substantial financial relief, they are primarily designed for patients with commercial insurance. They explicitly exclude individuals covered by government programs like Medicare and Medicaid ⁷⁷, who constitute a large segment of the population that may need these medications. Even for those who qualify for the "no coverage" options, the resulting monthly cost (often around $499-$650) can still be a significant financial burden.⁷⁷ Furthermore, these discounted cash prices typically do not count towards a patient's insurance deductible or annual out-of-pocket maximum ⁷⁷, meaning patients might still face high costs for other healthcare services. The terms and conditions of these programs can also be complex and are subject to change by the manufacturers.⁸³ Therefore, while these programs are a crucial stopgap for some, they do not represent a comprehensive solution to the systemic issues of affordability and access for these important medications. Patients on government plans or those who find even the discounted cash prices unaffordable will need to explore other avenues for assistance.

Other Avenues for Financial Support (If Manufacturer Programs Don't Apply)

For individuals who do not qualify for manufacturer savings programs or still find the costs prohibitive, other options for financial assistance may be limited but are worth exploring:

Patient Assistance Programs (PAPs) via Non-Profit Foundations: Some independent, non-profit charitable foundations operate patient assistance programs that can help cover out-of-pocket costs for medications. These programs often have specific eligibility criteria, which may include income limits, and they sometimes provide assistance to Medicare patients. Funding for these programs can be limited and may vary. An example mentioned in relation to Zepbound is the Patient Advocate Foundation (PAF) Co-Pay Relief program, though specific eligibility for these drugs would need to be verified.⁸⁵
State Prescription Assistance Programs (SPAPs): Some states have their own programs to help eligible residents pay for prescription medications. Coverage for GLP-1 agonists for weight loss through SPAPs is not widespread but checking the resources available through one's state department of health or aging may be worthwhile.
Negotiating Drug Prices with Insurance Company or PBM: It is generally not feasible for individual patients to directly negotiate drug prices with their insurance company or PBM.⁴² PBMs conduct these negotiations with drug manufacturers at a plan level to secure rebates and determine formulary placement, and these negotiations are not typically open to individual patient intervention.⁴²

It is important for patients to have realistic expectations about these alternative financial support options, as they may not always be available or provide sufficient assistance for such high-cost medications.

What If All Appeals Fail? Exploring Your Alternatives

Despite best efforts, there will be instances where insurance coverage for Wegovy or Zepbound cannot be secured, even after exhausting all levels of appeal. In such situations, it is important not to lose hope but to explore alternative pathways to manage weight and improve health.

Don't Give Up on Your Health Goals: Other Effective Weight Management Medications

If Wegovy or Zepbound are not accessible due to cost or coverage denials, patients should discuss other FDA-approved weight management medications with their doctor. While GLP-1 agonists are highly effective, other classes of drugs may offer viable alternatives, potentially with better insurance coverage or lower out-of-pocket costs.⁸⁷

Examples of alternative prescription weight loss medications include ⁸⁸:

Qsymia (phentermine/topiramate extended-release): An oral combination medication that works by suppressing appetite and increasing feelings of fullness.
Contrave (naltrexone/bupropion extended-release): An oral combination medication that targets brain pathways involved in hunger and cravings; may be particularly helpful for individuals with emotional eating patterns.
Orlistat (Xenical - prescription; Alli - over-the-counter): An oral medication that works in the digestive system to block the absorption of some dietary fat.
Phentermine (e.g., Adipex-P, Lomaira): An oral stimulant medication that suppresses appetite, typically approved for short-term use (a few weeks).

These alternatives have different mechanisms of action, efficacy levels, and side effect profiles compared to Wegovy and Zepbound. A thorough discussion with a healthcare provider is necessary to determine if any of these are a suitable and safe option based on the patient's individual health status and medical history. Some of these alternatives may also be listed on an insurer's formulary as preferred options or required as part of step therapy before GLP-1s are considered.²⁵

The Power of Lifestyle: Diet, Exercise, and Behavioral Support

Regardless of medication accessibility, comprehensive lifestyle modifications remain the cornerstone of effective and sustainable weight management and overall health improvement.⁵⁵ Even when GLP-1 medications are used, they are intended to be an adjunct to, not a replacement for, healthy habits.

Key lifestyle components include:

Sustainable Eating Patterns: Focus on creating a balanced and nutritious dietary pattern that can be maintained long-term. This often involves increasing fiber intake from whole grains, fruits, vegetables, and legumes; choosing lean protein sources; incorporating healthy fats; and practicing portion control and moderation, rather than adopting overly restrictive or fad diets.⁹²
Regular Physical Activity: Aim for at least 150 minutes of moderate-intensity aerobic activity (like brisk walking or cycling) or 75 minutes of vigorous-intensity aerobic activity (like jogging or running) per week, spread throughout the week. Incorporating muscle-strengthening activities (strength training) at least two days a week is also recommended.⁹²
Behavioral Support and Modification: Addressing the behavioral and psychological aspects of eating and weight is crucial. This can involve strategies such as cognitive-behavioral therapy (CBT) to identify and change unhelpful thought patterns and behaviors, mindfulness practices to increase awareness of hunger and satiety cues, setting realistic and achievable goals, and developing healthy coping mechanisms for stress and emotional triggers.⁵⁷
Prioritizing Sleep and Stress Management: Adequate sleep and effective stress management are increasingly recognized as important factors in weight regulation and overall well-being. Poor sleep can disrupt appetite-regulating hormones, and chronic stress can lead to unhealthy eating behaviors.⁹³

Many structured weight management programs, including those that may be required by insurance companies before approving medication, incorporate these multidisciplinary approaches.

Discussing Bariatric Surgery with Your Doctor

For individuals with severe obesity for whom medications are not accessible or effective, and who have not achieved sufficient health improvement with lifestyle changes alone, metabolic and bariatric surgery may be a medically appropriate and effective treatment option to discuss with their doctor.²⁵

Coverage and Effectiveness: Bariatric surgery is often covered by insurance plans (reportedly around 95% of plans ²⁵), including Medicare and many state Medicaid programs, when specific medical criteria are met.⁶¹ It has been shown to lead to significant and durable weight loss, as well as remission or improvement of many obesity-related comorbidities, such as type 2 diabetes, hypertension, sleep apnea, and heart disease.⁷⁴
A healthcare provider specializing in obesity medicine or a bariatric surgeon can evaluate whether an individual is a suitable candidate for surgery and discuss the potential benefits and risks.

Finding Clinical Trials for New Options

The field of obesity medicine is rapidly advancing, with numerous new medications and treatment approaches currently under investigation in clinical trials.¹⁷ Participating in a clinical trial could provide access to these novel treatments before they are widely available.

Resources for finding clinical trials include:

ClinicalTrials.gov: This is a comprehensive database of publicly and privately funded clinical studies conducted around the world. Patients can search for trials related to overweight or obesity that are actively recruiting participants.⁹⁷
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): The NIDDK, part of the National Institutes of Health (NIH), conducts and supports many clinical trials in obesity and related conditions. Their website provides information on these studies.⁹⁷
Professional Organizations: Organizations such as the Obesity Medicine Association or The Obesity Society may also have information on ongoing research or connect patients with research centers.

Patients interested in clinical trials should discuss this option with their doctor to determine if participation is appropriate for their individual situation.

Support Groups for Ongoing Encouragement and Shared Experiences

Dealing with the challenges of obesity and navigating treatment access can be emotionally taxing. Connecting with others who have similar experiences can provide invaluable emotional support, practical tips, and a sense of community.

Support groups and resources include:

Obesity Action Coalition (OAC): In addition to advocacy resources, the OAC offers community discussion forums and events where individuals can connect with peers.⁶⁹
Overeaters Anonymous (OA): OA is a 12-step fellowship for individuals recovering from compulsive eating and unhealthy relationships with food and body image. They offer face-to-face, online, and telephone meetings.⁶⁹

These support networks can help individuals feel less isolated and more empowered throughout their weight management journey.

Conclusion: Taking Control of Your Health Journey

The emergence of highly effective medications like Wegovy and Zepbound has undoubtedly brought new hope and possibilities for individuals struggling with obesity and its related health consequences. However, as this guide has detailed, accessing these treatments in 2025 often involves navigating a complex and sometimes frustrating insurance landscape.

Key Takeaways:

Wegovy and Zepbound offer significant clinical benefits, including substantial weight loss and, for specific patient populations, reduction in cardiovascular risk (Wegovy) or improvement in obstructive sleep apnea (Zepbound). These additional FDA-approved indications can be pivotal for securing coverage, especially under plans like Medicare that restrict coverage for drugs solely for weight loss.
The insurance approval process, particularly prior authorization, is a standard hurdle. Being thoroughly prepared with detailed medical documentation, a comprehensive history of previous weight loss attempts (including diet, exercise, and prior medications), and strong support from a healthcare provider are crucial for a successful PA submission.
Insurance denials are common but not necessarily the final answer. Patients have the right to appeal these decisions, first through internal appeals with the insurer and then, if necessary, through an independent external medical review. Persistence, coupled with a well-documented case addressing the specific reasons for denial, can often lead to an overturned decision. Appeal success rates are significant enough to make the effort worthwhile.
Manufacturer savings programs can substantially reduce out-of-pocket costs for commercially insured patients, both those with and without direct coverage for the medications. However, these programs have limitations, often exclude government beneficiaries, and may not make the drugs affordable for everyone.
If coverage for Wegovy or Zepbound cannot be obtained, alternative FDA-approved weight management medications, comprehensive lifestyle interventions (diet, exercise, behavioral support), and, for appropriate candidates, bariatric surgery remain important and effective options to discuss with a healthcare provider. The field of obesity treatment continues to evolve, with new therapies in clinical trials offering future hope.

Reinforcing Patient Empowerment:

Ultimately, navigating the path to accessing Wegovy or Zepbound requires patients to become active and informed participants in their own healthcare. This means understanding their insurance policy, diligently preparing for the prior authorization process, and being ready to advocate for themselves if faced with a denial. As often stated, the patient is their own best advocate.65

The information and strategies outlined in this guide are intended to empower individuals with the knowledge needed to approach these challenges with greater confidence. By partnering closely with healthcare providers, leveraging available resources from patient advocacy groups, and maintaining persistence, patients can increase their chances of accessing the treatments they need and take meaningful steps toward improving their health and well-being. The journey may be complex, but with the right tools and a proactive approach, it is a journey that can be successfully navigated.

Works cited

Novo Nordisk expands patient access to authentic, FDA-approved Wegovy® via collaborations with multiple telehealth organizations - PR Newswire, accessed May 10, 2025, https://www.prnewswire.com/news-releases/novo-nordisk-expands-patient-access-to-authentic-fda-approved-wegovy-via-collaborations-with-multiple-telehealth-organizations-302441147.html
Zepbound on Track to Transform 2025 Healthcare Landscape - NFP, accessed May 10, 2025, https://www.nfp.com/insights/zepbound-on-track-to-transform-2025-healthcare-landscape/
Frequently Asked Questions | Wegovy® (semaglutide) - novoMEDLINK, accessed May 10, 2025, https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/frequently-asked-questions.html
How Wegovy works: Mechanism of action explained - Medical News Today, accessed May 10, 2025, https://www.medicalnewstoday.com/articles/drugs-wegovy-how-it-works
FDA Approves First Medication for Obstructive Sleep Apnea, accessed May 10, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
How Zepbound works: Mechanism of action explained - Medical News Today, accessed May 10, 2025, https://www.medicalnewstoday.com/articles/drugs-zepbound-how-it-works
www.accessdata.fda.gov, accessed May 10, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf
Zepbound vs. Wegovy: Differences Between Weight-Loss Medications - GoodRx, accessed May 10, 2025, https://www.goodrx.com/conditions/weight-loss/zepbound-vs-wegovy
www.accessdata.fda.gov, accessed May 10, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
Press releases - Novo Nordisk, accessed May 10, 2025, https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167030
Why Your Cardiologist May Prescribe Semaglutide (Wegovy) > News > Yale Medicine, accessed May 10, 2025, https://www.yalemedicine.org/news/why-your-cardiologist-may-prescribe-semaglutide-wegovy
FDA Approves New Medication for Chronic Weight Management, accessed May 10, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
FDA Approves Zepbound as First Drug for Obstructive Sleep Apnea - MedCentral, accessed May 10, 2025, https://www.medcentral.com/pulmonology/zepbound-label-expansion-could-broaden-the-sleep-apnea-armamentarium
Check Your Cost and Coverage | Wegovy® (semaglutide) Injection 2.4 mg, accessed May 10, 2025, https://www.wegovy.com/coverage-and-savings/check-your-cost-and-coverage.html
Novo Nordisk Expands Discounted Access to Wegovy - Pharmaceutical Executive, accessed May 10, 2025, https://www.pharmexec.com/view/novo-nordisk-expands-discounted-access-wegovy
SB 25-048: DIABETES PREVENTION & OBESITY TREATMENT ACT - Colorado General Assembly |, accessed May 10, 2025, https://leg.colorado.gov/sites/default/files/documents/2025A/bills/fn/2025a_sb048_00.pdf
Outlook for obesity in 2025: more than a transition year - IQVIA, accessed May 10, 2025, https://www.iqvia.com/locations/emea/blogs/2025/01/outlook-for-obesity-in-2025-more-than-a-transition-year
NovoCare Pharmacy may improve access to Wegovy, but concerns about affordability remain - Healio, accessed May 10, 2025, https://www.healio.com/news/endocrinology/20250307/novocare-pharmacy-may-improve-access-to-wegovy-but-concerns-about-affordability-remain
How to Appeal Wegovy Coverage Denial - NowPatient, accessed May 10, 2025, https://nowpatient.com/blog/how-to-appeal-wegovy-coverage-denial
MassHealth Coverage of Weight Loss Drugs - Mass.gov, accessed May 10, 2025, https://www.mass.gov/doc/issue-3-october-2024-0/download
Zepbound Formulary Denials Explained - Honest Care, accessed May 10, 2025, https://www.findhonestcare.com/denial-reasons/zepbound-formulary-denials-explained
A step by step guide to obtaining insurance Coverage for GLP-1 ..., accessed May 10, 2025, https://poundofcureweightloss.com/insurance-coverage-for-glp-1-medications/
Is Zepbound covered by insurance? - Medical News Today, accessed May 10, 2025, https://www.medicalnewstoday.com/articles/drugs-is-zepbound-covered-by-insurance
Is Zepbound Covered by Insurance? Find Out How You Can Ensure Coverage, accessed May 10, 2025, https://atlantamedicalinstitute.com/is-zepbound-covered-by-insurance-find-out-how-you-can-ensure-coverage/
What to Do When Your Insurance Denies Zepbound or Wegovy - A Pound of Cure | A Bariatric Surgery and Non-Surgical Weight Loss practice in Tucson, AZ, accessed May 10, 2025, https://poundofcureweightloss.com/insurance-denies-zepbound-or-wegovy/
Live Updates: Tracking Insurance Coverage for GIP and GLP-1 Agonists Like Zepbound and Wegovy - GoodRx, accessed May 10, 2025, https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds
GLP-1 Drugs in 2025: Cost, access and future of obesity treatment - WTW, accessed May 10, 2025, https://www.wtwco.com/en-us/insights/2025/04/glp-1-drugs-in-2025-cost-access-and-the-future-of-obesity-treatment
Aetna to leave ACA marketplace while CVS partners with Novo Nordisk on Wegovy, accessed May 10, 2025, https://www.healthcare-brew.com/stories/2025/05/02/aetna-leave-aca-marketplace-cvs-partners-novo-nordisk-wegovy
CVS plans to exit ACA individual exchanges, strikes Wegovy deal with Novo Nordisk, accessed May 10, 2025, https://www.healthcaredive.com/news/cvs-aetna-exit-aca-novo-nordisk-wegovy-deal/746833/
CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss - Formulary Watch, accessed May 10, 2025, https://www.formularywatch.com/view/cvs-caremark-to-place-wegovy-as-preferred-glp-1-for-weight-loss
CVS Caremark Makes Wegovy Preferred Weight-Loss Medication, accessed May 10, 2025, https://www.drugtopics.com/view/cvs-caremark-makes-wegovy-preferred-weight-loss-medication
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health - WTHR, accessed May 10, 2025, https://www.wthr.com/article/news/health/eli-lilly-star-weight-loss-drug-zepbound-faces-coverage-challenge-from-cvs-health-wegovy-saxenda/531-649a14a0-c42c-4917-af01-b8701a477788
Medicare Drops Plan to Cover Obesity Drugs - Fingerlakes1.com, accessed May 10, 2025, https://www.fingerlakes1.com/2025/04/05/medicare-obesity-drug-coverage-wegovy-zepbound-2025/
Trump Scraps Biden's Proposed Medicare Coverage for Obesity Drugs - BioSpace, accessed May 10, 2025, https://www.biospace.com/policy/trump-scraps-bidens-proposed-medicare-coverage-for-obesity-drugs
Does Medicare Cover Weight Loss Drugs in 2025? - Wellcare, accessed May 10, 2025, https://www.wellcare.com/en/resources/does-medicare-cover-weight-loss-drugs
Expanded Coverage Options - Serve You Rx News, accessed May 10, 2025, https://serveyourx.com/news-blog/new-for-2025-expanded-coverage-options-to-better-serve-your-clients/
Wegovy approved for cutting cardiovascular disease risk - RACGP, accessed May 10, 2025, https://www1.racgp.org.au/newsgp/clinical/wegovy-approved-for-cardiovascular-disease-in-over?feed=RACGPnewsGPArticles
Medicare and Zepbound: Coverage, cost, and more - Medical News Today, accessed May 10, 2025, https://www.medicalnewstoday.com/articles/is-zepbound-covered-by-medicare
GLP-1 Weight Loss Drugs: Coverage Under Medicaid and Other Health Plans | MultiState, accessed May 10, 2025, https://www.multistate.us/insider/2025/3/17/glp-1-weight-loss-drugs-coverage-under-medicaid-and-other-health-plans
Zepbound and phentermine added to preferred drug list - UHCprovider.com, accessed May 10, 2025, https://www.uhcprovider.com/en/resource-library/news/2025/ma-medicaid-zepbound-phentermine.html
How to Choose the Best Pharmacy Benefit Manager (PBM) for Your Company in 2025, accessed May 10, 2025, https://intercept.health/insights/blog/how-to-choose-the-best-pharmacy-benefit-manager-pbm-for-your-company-in-2025/
Prescription Drug Prices, Rebates, and Insurance Premiums - U.S. Department of Labor, accessed May 10, 2025, https://www.dol.gov/sites/dolgov/files/ebsa/laws-and-regulations/laws/no-surprises-act/2024-appendix-prescription-drug-prices.pdf
Zepbound Prior Authorization Criteria for Weight Loss - Pharma Giant, accessed May 10, 2025, https://pharmagiant.com/zepbound-prior-authorization-criteria/
Prior Authorization for Wegovy: How to Get Approved | Ro, accessed May 10, 2025, https://ro.co/weight-loss/prior-authorization-for-wegovy/
Appealing Wegovy denial: Prior authorization, letters, and tips - Medical News Today, accessed May 10, 2025, https://www.medicalnewstoday.com/articles/drugs-how-to-appeal-wegovy-denial
Obesity GLP-1 Agonists – PA, NF - Pharmacy Prior Authorization Criteria - www.westernhealth.com, accessed May 10, 2025, https://www.westernhealth.com/provider/prior-authorization-criteria/?category=Custom&glId=GL-162307
5 steps to appeal a Zepbound coverage denial - Honest Care, accessed May 10, 2025, https://www.findhonestcare.com/blog-posts/steps-to-appeal-your-zepbound-claim-denial
New coverage requirements for GLP-1 medications: Chevron prescription drug program, accessed May 10, 2025, https://hr2.chevron.com/-/media/hr2/document-library/SMM/SMM_2025_PDP_GLP1NewRequirements_FINAL.pdf
GLP-1 Receptor Agonists MAAC 07.07.25, accessed May 10, 2025, https://www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/about/dhs-information/documents/informationforadvocatesandstakeholders/maac/glp-1-receptor-agonists-maac-07-07-25.pdf
zepbound.lilly.com, accessed May 10, 2025, https://zepbound.lilly.com/assets/pdf/letter_of_medical_necessity.pdf
9 Steps To Appeal A Prior Authorization Denial For Weight Loss Meds, accessed May 10, 2025, https://www.helloklarity.com/post/appeal-prior-authorization-denial/
Health Insurance - TN.gov, accessed May 10, 2025, https://www.tn.gov/partnersforhealth/health-options/health.html
External Review | HealthCare.gov, accessed May 10, 2025, https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
Obesity Algorithm | Obesity Medicine Association, accessed May 10, 2025, https://obesitymedicine.org/resources/obesity-algorithm/
Guidelines for GLP injections - Pharmko, accessed May 10, 2025, https://www.pharmko.com/blog/guidelines-for-glp-injections
Obesity Medicine Resources, accessed May 10, 2025, https://obesitymedicine.org/resources/
The Four Pillars of Obesity Treatment, accessed May 10, 2025, https://obesitymedicine.org/about/four-pillars/
Wegovy Health Insurance Denial Attorney - Law Offices of Scott Glovsky, accessed May 10, 2025, https://scottglovsky.com/insurance-bad-faith/health-claim-denial/wegovy-health-insurance-denial/
Is Zepbound covered by insurance? - Medical News Today, accessed May 10, 2025, https://www.medicalnewstoday.com/articles/drugs-is-zepbound-covered-by-insurance?utm_source=ReadNext
Access to Care Resources - Obesity Action Coalition, accessed May 10, 2025, https://www.obesityaction.org/advocacy/resources/access-to-care-resources/
What to do When You're Denied (Bariatric) Weight-loss Surgery - Obesity Action Coalition, accessed May 10, 2025, https://www.obesityaction.org/resources/what-to-do-when-youre-denied-bariatric-weight-loss-surgery/
How to organize medical paperwork, accessed May 10, 2025, https://www.getorganizedalready.com/how-to-organize-medical-paperwork/
Step-by-Step Guide to Obtaining Insurance Coverage for GLP-1 Medications like Zepbound and Wegovy - YouTube, accessed May 10, 2025, https://www.youtube.com/watch?v=IBbV-CLgN8Y
Questions to Ask Your Doctor About Wegovy for Weight Loss - Healthgrades Health Library, accessed May 10, 2025, https://resources.healthgrades.com/drugs/wegovy-for-weight-loss
Preparing to Talk With Your Health Care Provider - Wegovy.com, accessed May 10, 2025, https://www.wegovy.com/content/dam/wegovy/pdf/US21SEMO00922.pdf
Making Choices About Surgery, accessed May 10, 2025, https://asmbs.org/patients/making-choices/
Are you struggling to access obesity treatment due to insurance barriers/exclusions?, accessed May 10, 2025, https://www.obesityaction.org/action-through-advocacy/access/
OAC Action Center - Obesity Action Coalition, accessed May 10, 2025, https://www.obesityaction.org/action-center/
8 of the Best Organizations for Obesity Support - Everyday Health, accessed May 10, 2025, https://www.everydayhealth.com/diet-nutrition/the-best-organizations-for-obesity-support/
Obesity Action Coalition Celebrates 20 Years of Education, Support and Advocacy at the 2025 Your Weight Matters National Convention, accessed May 10, 2025, https://www.obesityaction.org/obesity-action-coalition-celebrates-20-years-of-education-support-and-advocacy-at-the-2025-your-weight-matters-national-convention/
FREE Pocket Guide - The Obesity Society, accessed May 10, 2025, https://www.obesity.org/meetings-education/free-obesity-treatment-ebook/
We Commit to Care for Obesity Care Week and Beyond - ConscienHealth, accessed May 10, 2025, https://conscienhealth.org/2025/03/we-commit-to-care-for-obesity-care-week-and-beyond/
American Society for Metabolic and Bariatric Surgery, Obesity Groups Take Aim at States That Deny Coverage of Obesity Treatment Under Affordable Care Act, accessed May 10, 2025, https://asmbs.org/news_releases/american-society-for-metabolic-and-bariatric-surgery-obesity-groups-take-aim-at-states-that-deny-coverage-of-obesity-treatment-under-affordable-care-act/
For Patients - American Society for Metabolic and Bariatric Surgery, accessed May 10, 2025, https://asmbs.org/for-patients/
American Board of Obesity Medicine: Home, accessed May 10, 2025, https://www.abom.org/
OMA Member Resources - Obesity Medicine Association, accessed May 10, 2025, https://obesitymedicine.org/membership/member-resources/
Wegovy® (semaglutide) injection 2.4 mg Savings Offer & Support ..., accessed May 10, 2025, https://www.novocare.com/obesity/products/wegovy/savings-offer.html
Obesity Savings Card Program | NovoCare®, accessed May 10, 2025, https://www.novocare.com/eligibility/obesity-savings-card.html
LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients, accessed May 10, 2025, https://www.globenewswire.com/news-release/2025/04/29/3070180/6480/en/LifeMD-Announces-Plans-to-Expand-Affordable-Access-to-Wegovy-for-Cash-Pay-Patients.html
Wegovy® Savings Card | Wegovy® (semaglutide) Injection 2.4 mg, accessed May 10, 2025, https://www.wegovy.com/coverage-and-savings/save-on-wegovy.html
Wegovy Coupons and Savings Options | 2025 - Healthline, accessed May 10, 2025, https://www.healthline.com/health/drugs/wegovy-coupon
BREAKING : Lilly Extends Zepbound Savings Cards Through End of 2025 - On The Pen, accessed May 10, 2025, https://www.onthepen.com/post/breaking-lilly-extends-zepbound-savings-cards-through-end-of-2025
zepbound.lilly.com, accessed May 10, 2025, https://zepbound.lilly.com/assets/pdf/2025_terms_and_conditions.pdf?utm_source=patient_resource&utm_medium=sms&utm_campaign=cy24_incretins-c-zepbound_retention&utm_content=pp-zp-us-1146
Savings Card, Cost & Coverage Support | Zepbound® (tirzepatide) - Eli Lilly, accessed May 10, 2025, https://zepbound.lilly.com/coverage-savings
Zepbound Savings Card - Covered benefit - PrescriberPoint, accessed May 10, 2025, https://prescriberpoint.com/therapies/zepbound-487cd7e/financial-assistance/zepbound-savings-card---covered-benefit
Assessing the Feasibility and Likelihood of Policy Options to Lower Specialty Drug Costs, accessed May 10, 2025, https://www.researchgate.net/publication/384402201_Assessing_the_Feasibility_and_Likelihood_of_Policy_Options_to_Lower_Specialty_Drug_Costs
What can I do if my health insurance denied coverage of my ..., accessed May 10, 2025, https://www.healthinsurance.org/faqs/what-can-i-do-if-my-health-insurance-denied-coverage-of-my-medication/
4 Alternatives to GLP-1s for Weight Loss - GoodRx, accessed May 10, 2025, https://www.goodrx.com/conditions/weight-loss/glp-1-alternatives
2025 Express Scripts National Preferred Formulary Exclusions, accessed May 10, 2025, https://www.express-scripts.com/pdf/formulary/NPF_Preferred_Formulary_Exclusions2025.pdf
FDA officials warn of fake weight loss drugs; ban compounded versions of popular medications - UCHealth, accessed May 10, 2025, https://www.uchealth.org/today/what-to-do-about-fake-weight-loss-drugs-and-ban-on-compounded-versions/
Wegovy prior authorization criteria: Blue Cross Blue Shield - SingleCare, accessed May 10, 2025, https://www.singlecare.com/blog/wegovy-prior-authorization-criteria-blue-cross-blue-shield/
Don't diet in 2025 — do this instead - Sharp HealthCare, accessed May 10, 2025, https://www.sharp.com/health-news/dont-diet-in-2025-do-this-instead
Top Weight Loss Trends & Tips for Success in 2025 - Noom, accessed May 10, 2025, https://www.noom.com/blog/weight-management/your-guide-to-weight-loss-in-2025-trends-tips-and-timeless-strategies/
Resources - American Society for Metabolic and Bariatric Surgery, accessed May 10, 2025, https://asmbs.org/resources/metabolic-and-bariatric-surgery/
Obesity trials on trial: How major late-phase clinical trials for anti-obesity medications reflect true obese populations- and what can be done when they don't. - IQVIA, accessed May 10, 2025, https://www.iqvia.com/locations/emea/blogs/2025/03/obesity-trials-on-trial
World Obesity Day 2025: Recent Developments and the Road ..., accessed May 10, 2025, https://www.medpace.com/blog/world-obesity-day-2025-recent-developments-and-the-road-ahead/
Clinical Trials for Overweight & Obesity - NIDDK, accessed May 10, 2025, https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/clinical-trials

Nutrition Obesity Research Centers - NIDDK, accessed May 10, 2025, https://www.niddk.nih.gov/research-funding/research-programs/nutrition-obesity-research-centers